SCHEMBL16189062

SCHEMBL16189062

Cc1ncccc1-c1ccc(-c2nc(-c3ccccc3)nc(-c3ccccc3)n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.57
MKNK2 Q9HBH9 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.52
DHODH Q02127 3/20 0.50
PTGS1 P23219 2/20 0.46
PTGS2 P35354 2/20 0.46
LMNA P02545 2/20 0.43
TOP1 P11387 4/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
ADORA3 P0DMS8 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
ADORA1 P30542 1/20 0.40
EDNRB P24530 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16189413 0.98 MKNK1 (0.55) MKNK1MKNK2L3MBTL1DHODHPTGS1
SCHEMBL16189249 0.91 MKNK1 (0.49) MKNK1MKNK2L3MBTL1DHODHPTGS1
SCHEMBL16189042 0.89 MKNK1 (0.48) MKNK1MKNK2L3MBTL1DHODHPTGS1
SCHEMBL17932781 0.89 MKNK1 (0.47) MKNK1MKNK2L3MBTL1DHODHPTGS1
SCHEMBL21982349 0.89 MKNK1 (0.47) MKNK1MKNK2L3MBTL1DHODHPTGS1
SCHEMBL16189410 0.89 MKNK1 (0.47) MKNK1MKNK2L3MBTL1DHODHPTGS1
SCHEMBL15730173 0.89 MKNK1 (0.59) MKNK1MKNK2DHODHPTGS1PTGS2
SCHEMBL2084918 0.89 MKNK1 (0.58) MKNK1MKNK2DHODHPTGS1PTGS2
SCHEMBL30563610 0.89 MKNK1 (0.58) MKNK1MKNK2DHODHPTGS1PTGS2
SCHEMBL17532859 0.88 L3MBTL1 (0.47) MKNK1MKNK2L3MBTL1DHODHLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
WO-2014171541-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE ELEMENT AND APPLICATION THEREFOR 東ソー株式会社 (JP) 2014-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION AOC2, AZI2, KCNH2 MKNK1 4233/4885MKNK2 3825/4885L3MBTL1 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.